Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Aquestive Therapeutics, Inc. - Common Stock (NQ:AQST)

4.105 +0.025 (+0.61%)
Streaming Delayed Price Updated: 9:57 AM EDT, Apr 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 88,077
Open 4.060
Bid (Size) 4.100 (8,000)
Ask (Size) 4.110 (400)
Prev. Close 4.080
Today's Range 4.060 - 4.129
52wk Range 2.120 - 7.550
Shares Outstanding 38,886,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors They Have Until May 4th to Seek Lead Plaintiff Role
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST
From Pomerantz LLP
Via GlobeNewswire

Performance

YTD
-36.4%
-36.4%
1 Month
+2.1%
+2.1%
3 Month
+26.7%
+26.7%
6 Month
-41.4%
-41.4%
1 Year
+45.1%
+45.1%

More News

Read More
News headline image
Robbins LLP Urges AQST Stockholders to Contact the Firm for Information About the Class Action Against Aquestive Therapeutics, Inc.
From Robbins LLP
Via Business Wire
News headline image
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQST
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST
From Pomerantz LLP
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc. (AQST)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors They Have Until May 4th to Seek Lead Plaintiff Role
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
AQUESTIVE THERAPEUTICS, INC. (AQST) DEADLINE ALERT Bernstein Liebhard LLP Reminds Aquestive Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST
From Pomerantz LLP
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc. (AQST)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
AQUESTIVE THERAPEUTICS, INC. (AQST) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Aquestive Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
AQST SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST
From Pomerantz LLP
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc. (AQST)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors with Significant Losses to Contact the Firm Before Upcoming Lead Plaintiff Deadline
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQST
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
AQUESTIVE THERAPEUTICS, INC. (AQST) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Aquestive Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
AQST INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics Investors of Securities Class Action Deadline on May 4, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST
From Pomerantz LLP
Via GlobeNewswire
News headline image
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Claims CEO Allegedly Misrepresented Company Prospects: Levi & Korsinsky
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc. (AQST)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQST
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
AQUESTIVE THERAPEUTICS, INC. (AQST) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Aquestive Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire

Frequently Asked Questions

Is Aquestive Therapeutics, Inc. - Common Stock publicly traded?
Yes, Aquestive Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Aquestive Therapeutics, Inc. - Common Stock trade on?
Aquestive Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aquestive Therapeutics, Inc. - Common Stock?
The ticker symbol for Aquestive Therapeutics, Inc. - Common Stock is AQST on the Nasdaq Stock Market
What is the current price of Aquestive Therapeutics, Inc. - Common Stock?
The current price of Aquestive Therapeutics, Inc. - Common Stock is 4.105
When was Aquestive Therapeutics, Inc. - Common Stock last traded?
The last trade of Aquestive Therapeutics, Inc. - Common Stock was at 04/27/26 09:57 AM ET
What is the market capitalization of Aquestive Therapeutics, Inc. - Common Stock?
The market capitalization of Aquestive Therapeutics, Inc. - Common Stock is 159.63M
How many shares of Aquestive Therapeutics, Inc. - Common Stock are outstanding?
Aquestive Therapeutics, Inc. - Common Stock has 160M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.